

version of the claims includes language that correctly recites how many times each claim has been amended. This amendment is now believed to be in compliance with 37 C.F.R. § 1.121(c)(1)(i) and applicants respectfully request its entry and consideration. Please amend the application as follows.

IN THE CLAIMS

Please amend the claims as follows. A marked up version of these claim amendments is attached hereto.

13. (Thrice Amended) The protein of claim 67, wherein the target is a biological entity.

14. (Thrice Amended) The protein of claim 67, wherein the target is an organ, tumor, tissue, cell, virus, or microorganism.

E 1  
15. (Thrice Amended) The protein of claim 67, wherein the target is a synthetic or naturally occurring macromolecule.

16. (Thrice Amended) The protein of claim 67, wherein the target is a protein.

17. (Thrice Amended) The protein of claim 67, wherein the target is a cell surface protein.

18. (Thrice Amended) The protein of claim 67, wherein the target is an integrin.

19. (Thrice Amended) The protein of claim 67, wherein the target is an integrin that binds to an Arg-Gly-Asp tripeptide motif.

20. (Thrice Amended) The protein of claim 67, wherein the target is  $\alpha IIb\beta 3$  integrin.

21. (Thrice Amended) The protein of claim 67, wherein the target is  $\alpha v\beta 3$  integrin.

22. (Thrice Amended) The protein of claim 67, wherein the optimized, protein surface loop is a complementarity determining region of an IgG-like molecule.

23. (Thrice Amended) The protein of claim 67, wherein the optimized, surface loop is a complementarity determining region of an antibody molecule.  
*E  
com*

24. (Twice Amended) The protein of claim 23, wherein the complementarity determining region is heavy chain complementarity determining region 3 of monoclonal antibody Fab-9.

65. (Amended) The protein of claim 67, wherein the protein is loop-grafted tissue type plasminogen activator.